Early Experience of Aflibercept 8mg (EYLE® 8mg) in Routine Clinical Practice

News
Article

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Subscribe Now!
Recent Videos
Related Content
Three ways we’re building confidence through evidence in myopia management

Three ways we’re building confidence through evidence in myopia management

July 25th 2025
Article
Site Logo

Updates From Angiogenesis-2022

February 11th 2022
Podcast
Site Logo

Three-year outcomes of aflibercept 8mg in neovascular age related macular degeneration and diabetic macular edema

Sponsored by Bayer
June 25th 2025
Article
Site Logo

Updates from ASRS 2021

October 28th 2021
Podcast
Clinical outcomes and patient satisfaction achieved with a corneal approach for managing presbyopia – a case with special significance

Clinical outcomes and patient satisfaction achieved with a corneal approach for managing presbyopia – a case with special significance

Arnaldo Espaillat, MD
April 1st 2025
Article

Dr. Arnaldo Espaillat decided to undergo ZEISS PRESBYOND and shares how his own experience led him to expand his refractive portfolio with this corneal-based approach for patients without cataracts.

Site Logo

Every diopter counts when it comes to myopia management in children.

February 1st 2025
Article
© 2025 MJH Life Sciences

All rights reserved.